Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Always a sell-off before a huge run
This Will Drop like a Rock..BEWARE!!!!
Great thing is...they don't even need a product... other companies will need their patents
Good thing this stock has a reason than
Who thinks this is a week for a huge upwards turning point?....go
Have had Android since they came out....never a problem....will not go with anything else anytime soon
I have said it time and time again... EPGL will not be a sell out. All these patents, once approved, will make EPGL too lucrative to be bought out. Why sell your company when you can keep building on it?
Is it nonsense that the only two companies they own are nothing more than mom & pop businesses that has very little profit margins as well as all the lies they've told in the past couple years about big things coming....so what happened with all that.....explain please!!!!!
Considering the players involved here with EPGL....keeps me satisfied!
Highly believe this EPGL will not sell out...they have too much going for them to do so. Patents....new technology....not to mention possible newer tech coming from within this technology that could be implemented into other sources. Hugh licensing deals on horizon.
The market already aware of this post scam... that's why most have moved on.
My my...took another dive.... imagine that.
>>>>>Alert<<<<<< Scam Scam Scam
Most ppl got more than that tied up in their home...let me know when they are making money!!!!
Lol... PEANUTS!.. Company has been scamming too long. Do yourself a favor and do some DD you're own self! You definitely not getting my money sucks!
So you are saying you too soft to copy and paste actual fins cause you know they are making peanuts?
Did I miss something...did there reopen a plant? Pay their bills? Reimburse shareholders?. No? Then stfu till they do!
I keep seeing fins look great or awesome....so why not post what the actual fins are.....small potatoes!!!
Bottom not close yet
Surprise Surprise Surprise
Invest here...go broke here...period!
Knew that was coming
This one going down hard tomorrow.... No updates...no news....scam for several years.... Do your own DD!
This penny stock exists only to rob u of your money...... Think I'm wrong? Do yourself a favor and do some DD!
BOOM.....And we're Back!!!!
Stock up on NO news means one thing...scam!!!!!
EPGL created Eligibility when Coopersvision signed a deal with them
All the justification is there in full print. It just needs to be READ!!
Sell those shares.....plenty of us to pick up some on the way back up.....loving EPGL
Take notice about licensing new technologies!!!!!
Novartis Profit Dives 57% on Eye-Care Woes --2nd Update
Source: Dow Jones News
By John Letzing and Denise Roland
Novartis AG outlined plans to revive its ailing eye-care business as the unit contributed to a 57% decline in fourth-quarter net profit, but earnings were also hit by the strength of the U.S. dollar and a one-time charge related to losses at the Swiss drug giant's Venezuela business.
The company said it would narrow Alcon's focus to surgical equipment and vision-care products, such as contact lenses, by hiving off ophthalmic drugs into the company's giant pharmaceuticals division.
The Swiss firm also appointed former Hospira boss Mike Ball to lead the slimmed-down Alcon division, replacing Jeff George. Chief Executive Joe Jimenez said of Mr. George's departure: "He's had a tough year at Alcon and with all the changes Jeff felt now was a good time to step down." Mr. Ball left Hospira last year, after it was acquired by Pfizer Inc.
Novartis shares were down 3% at 81.15 Swiss francs on Wednesday afternoon.
Alcon has struggled recently amid increased competition in the lens implant market and the entry of cheaper copycats of some ophthalmic drugs. Stripping out the effect of the strong dollar, sales at the unit fell 6% in the fourth quarter, to $2.3 billion, while operating income decreased 36% to $132 million.
Mr. Jimenez said Novartis would invest about $200 million in a plan that should boost Alcon's performance, and that he expects the unit would begin to "return to growth by the end of this year."
Novartis's CEO, who had previously said he was open to selling off underperforming parts of Alcon, said that "for now" the company planned to keep all of the business.
Mr. Jimenez said separating the eye drugs from the surgical equipment and contact lenses would mean the remainder of Alcon could focus on a "surgical innovation model" which is centered on making incremental improvements based on feedback from surgeons, in contrast to the much longer time scale involved in pharmaceutical innovation. He said Novartis would license in new technologies to bolster the innovation pipeline for surgical devices. He added that the slimmed-down Alcon would also improve its customer service, which he admitted had suffered due to cost cuts.
The Alcon overhaul comes at a tough juncture for Novartis, which is bracing for its best-selling cancer drug Gleevec losing U.S. exclusivity in February. It said it expected revenue and profit for 2016 to be "broadly in line" with results in 2015.
The company is leaning heavily on two new launches--Entresto for heart failure and Cosentyx for psoriasis and certain rheumatic ailments--to help offset the expected sharp drop-off in Gleevec sales this year.
Entresto, which analysts expect to generate $5 billion in annual sales at its peak, has got off to a slow start as two-thirds of heart failure patients are covered by Medicare, which can delay reimbursement decisions for six months post-launch. The heart failure drug generated just $5 million in sales in the fourth quarter. David Epstein, head of Novartis' pharmaceuticals unit, said reimbursement for Entresto had improved "substantially" during January, with 70% of Medicare patients now covered. "In many ways, the full launch of the product is only just starting," he said.
Cosentyx by contrast, has progressed "strongly," said Novartis, bringing in $121 million of revenue in the fourth quarter.
For Novartis as a whole, net income fell to $1.05 billion in the quarter ended in December, compared with $2.45 billion in the same period a year earlier.
Revenue dipped 4% to $12.52 billion, the company said. Core net income, which strips out one-time events such as impairments or gains, fell 5% to $2.7 billion, Novartis said. Analysts had expected revenue of $12.7 billion and core net income of $2.7 billion.
As well as the drag from the weak Alcon unit, profit took a hit from a $346 million write-down on Novartis' Venezuela business, related largely to the currency impact of high inflation in the country. The decline was also sharpened by a one-off gain in the previous year of around $400 million from the sale of Novartis' shares in LTS Lohmann Therapie-Systeme AG.
Stripping out the effect of the strong dollar, revenue increased 4% and net income fell 34%. Mr. Jimenez said he expected the strong dollar to continue to affect reported results through 2016, but said the effect would lessen.
Novartis pharmaceuticals unit provided a bright spot for the results. Excluding the impact of the strong dollar, the unit posted a 9% increase in both revenue and operating income to $7.9 billion and $1.5 billion respectively. The company said its newer products generated nearly half of these sales.
On top of the Alcon restructuring, Novartis said it planned to move off-patent drugs worth around $900 million in sales from its pharmaceuticals unit into Sandoz, its generics business. Mr. Jimenez said he believed this would generate growth since those products would be more strongly promoted as part of Sandoz.
In addition, Novartis said it plans to take steps including centralizing manufacturing to reduce costs by $1 billion annually by 2020. The effort will involve one-time restructuring costs of about $1.4 billion spread over five years, Novartis said.
Write to John Letzing at john.letzing@wsj.com and Denise Roland at Denise.Roland@wsj.com
(END) Dow Jones Newswires
January 27, 2016 09:42 ET (14:42 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
?
$$$$$$$$ EPGL $$$$$$$$$
Typical penny stock here
EPGL has PROVEN they have technology to change the future with multiple companies in the very near future. Once EPGL's patents are approved, there will be No Stopping the success of EPGL. Take it or leave it...you're choice!
Go EPGL.....Patent Approval Soon!!!
Don't think they would be in negotiations that long without getting a lump sum.
No idea what you mean.
Evidence?..... There is a ton of evidence out there....but you have to actually do some work to get to the truth...alot like life.
Info is everywhere...previous posts has links.....check Zack's.com also.
Sure...y not....headed there anyway